Doxycycline-Associated Dual Cutaneous Adverse Reaction to the Drug (CARD): Case Report of Concurrent Photosensitivity and Morbilliform Exanthem to Doxycycline

Joanne S. Jacob 1, Philip R. Cohen 2

1. Medicine, Baylor College of Medicine, Houston, USA 2. Dermatology, San Diego Family Dermatology, National City, USA

Corresponding author: Joanne S. Jacob, joannej@bcm.edu

Abstract

Antibiotics have been observed to cause drug-induced reactions. These can include a cutaneous adverse reaction to the drug (CARD) such as photosensitivity. A 51-year-old woman initiated doxycycline monohydrate for rosacea. Within nine days, she developed two different, simultaneous skin rashes: a phototoxic reaction and a morbilliform drug eruption. The medication was stopped; topical and oral corticosteroids were initiated. Within two weeks, her rashes resolved. Common cutaneous adverse reactions to doxycycline include photosensitivity and morbilliform exanthem. Less common skin side effects include bullous eruptions, lupus-like eruptions, pigmentary disorders, and vasculitis. Albeit uncommon, doxycycline-associated dual CARD - such as the photosensitivity and morbilliform exanthem - may occur.

Categories: Dermatology

Keywords: adverse, antibiotics, cutaneous, dermatitis, doxycycline, drug, medication, morbilliform, photosensitivity, reaction

Introduction

Systemic antibiotics are commonly prescribed for the management of not only infections but also other conditions. However, antibiotics can be associated with numerous side effects. These include not only systemic reactions to the medication but also cutaneous adverse reaction to the drug (CARD) [1]. Doxycycline is a tetracycline derivative. It can be used in the management of bacterial skin infections like methicillin-resistant Staphylococcus aureus. Also, it is a mainstay therapy for cutaneous disorders such as acne and rosacea [2].

Photosensitivity has been associated with several drugs [1,3]. A morbilliform exanthem has also been observed in patients who are allergic to medication [4]. Features of a woman who started doxycycline monohydrate for the treatment of rosacea and developed a concurrent cutaneous adverse reaction to the antibiotic is described.

Case Presentation

A 51-year-old woman had a history of rosacea of several years duration. She had been evaluated and treated by numerous prior physicians. Her recent management included systemic erythromycin 500mg twice daily and topical 0.75% metronidazole gel; however, her symptoms and clinical appearance had worsened. Her management was changed. The erythromycin was discontinued, and doxycycline monohydrate 100 mg twice daily was started. Within nine days, she developed two different, yet concurrent, skin rashes to the doxycycline.

One of the skin lesions was limited to sun-exposed areas of the face and neck; it also affected the forearms corresponding to areas not covered by her shirt sleeves. There was pruritic macular erythema with telangiectasias on her face and chest. The lesions on her cheeks were not only secondary to rosacea but also exacerbated by sun exposure. There were also erythematous patches on her chest with distinctive sparing of the area between chin and neck, which had not exposed to the sun (Figure 1). Also, there was macular erythema on her forearms (Figure 2).
FIGURE 1: Phototoxic drug reaction to doxycycline in sun-exposed areas

A 51-year-old woman developed doxycycline-related phototoxic reaction. Views of face (a and b), neck (a, b, and c) and chest (a, b, and c) show telangiectasias (black asterisks), and pruritic macular erythema (black arrows) in the areas exposed to the sun. However, there is sparing on the skin between the chin and neck (within the black oval) that was not sun-exposed.

FIGURE 2: Doxycycline-associated phototoxic cutaneous adverse
reaction to the drug (CARD)

Distant (a) and closer (b) views of phototoxic drug reaction to doxycycline in a 51-year-old woman presenting as pruritic, macular erythema (black arrows) on the sun-exposed areas of the right forearm that were not covered by her shirt sleeve.

The second-skin rash was extremely pruritic. It consisted of morbilliform macules and confluent patches on non-sun exposed skin. The exanthem was present on her flanks and abdomen (Figure 3).

FIGURE 3: Doxycycline-related morbilliform drug eruption
Cutaneous adverse reaction to the drug (CARD) that developed nine days after beginning treatment with doxycycline. The right flank (a and b) and the abdomen (c and d) show distant (a and c) and closer (b and d) views of extremely pruritic morbilliform macules and confluent patches (black arrows) on non-sun exposed skin.

Management of the new CARD included stopping the doxycycline. The topical metronidazole gel was also discontinued. Oral antihistamines (loratadine 10mg in the morning and hydroxyzine 25mg in the evening) were started. A short course of oral prednisone was started: 60 mg each morning for six mornings followed by 40mg each morning for four mornings and then 20mg each morning for two mornings. Also, triamcinolone 0.1% cream was applied twice daily to all affected areas.

Follow-up after one week of treatment showed significant improvement of the pruritis and skin lesions. After two weeks of therapy, all of her symptoms and lesions had resolved. She resumed her topical rosacea regimen with twice daily application of the metronidazole gel.

Discussion
Tetracyclines are a class of antibiotics that include demeclocycline, doxycycline, minocycline, and tetracycline. The mechanism of action is binding to the 30s ribosomal subunit of bacteria and inhibiting bacterial protein synthesis when treating infection [2]. However, when the drug is used in acne and rosacea, the therapeutic effect may also be secondary to its anti-inflammatory properties. Systemic and cutaneous adverse reactions may occur in patients treated with tetracyclines.

Doxycycline CARD includes photosensitivity; also, patients may develop a morbilliform exanthem. Less common skin side effects include bullous eruptions, lupus-like eruptions, pigmentary disorders, and vasculitis [5-8]. The development of simultaneous or multiple doxycycline-induced CARD is unique; indeed, we are not aware of a previous description of this phenomenon. Photosensitivity to drugs includes photoallergic and phototoxic reactions. The occurrence of these varies. The incidence of photoallergic reactions is low, and phototoxic reactions are high (Table 3) [1,3,9-11].
### TABLE 1: Occurrence of drug-associated photoallergic and phototoxic reactions

| Characteristic       | Photoallergic reactions | Phototoxic reactions |
|----------------------|-------------------------|---------------------|
| Incidence            | Uncommon                | Common              |
| Prior exposure to drug| Required                | Not required        |
| Dose-dependence      | No; can occur with low doses | Yes; increases with higher dose |

The clinical characteristics of photosensitivity drug reactions are summarized in Table 2 [1,5-9,11]. Photoallergic reactions appear as eczematous lesions that can occur on both sun-exposed and non-exposed skin. In contrast, phototoxic reactions typically present as edematous patches on sun-exposed skin; vesicle and bullae formation may occur.

### TABLE 2: Clinical presentation of drug-associated photoallergic and phototoxic reactions

| Characteristic       | Photoallergic reactions                                                                 | Phototoxic reactions                                                                 |
|----------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Onset                | Does not occur following initial exposure                                               | Occurs following initial exposure                                                     |
| Time of onset        | Occurs one to three days after initiation of drug                                        | Occurs within minutes to hours after initiation of drug                                |
| Appearance           | Dermatitis                                                                              | Sunburn-like inflammation                                                              |
| Distribution         | Starts on sun-exposed areas and spreads throughout entire body                         | Only sun-exposed areas                                                                 |
| Morphology           | Eczematous lesions with pruritis                                                        | Erythematous and edematous lesions; overlying blisters may occur                     |

The histology of photoallergic reactions shows spongiosis of the epidermis and infiltration of the dermis with lymphocytes. In contrast, the pathologic changes of phototoxic reactions show necrosis of the epidermis and infiltration of the dermis with lymphocytes, macrophages, and neutrophils [9,10].

The management of photosensitivity reactions usually involves stopping the causative agent. Resolution of the reaction with pigmentedary changes may occur; however, this is uncommon in photoallergic reactions and is common in phototoxic reactions [9,11]. Reduction of ultraviolet radiation exposure, in addition to the use of sunscreen and protective clothing, can decrease the occurrences of the CARD [10].

In addition to tetracyclines, other antibiotics are also associated with photosensitivity (Table 3) [11-20]. Fluoroquinolones, sulfonamides and tetracyclines are the most common culprits [13,14,16-20]. However, cephalosporins and penicillins have also been rarely observed to cause photosensitivity [12,15].

### TABLE 3: Systemic antibiotics associated with photosensitivity

| Class of drug | Drug                                                                 | References |
|---------------|----------------------------------------------------------------------|------------|
| Cephalosporins| Ceftazidime                                                          | [12]       |
| Fluoroquinolones| Ciprofloxacin, enoxacin, levofloxacin, ofloxacin, sitafloxacin, sparflloxacin | [13,14]   |
| Penicillins   | Amoxicillin                                                          | [15]       |
| Sulfonamides  | Dapsone, trimethoprim-sulfamethoxazole                               | [16,17]    |
| Tetracyclines | Demethylchlortetracycline, doxycycline, minocycline, tetracycline   | [18-20]    |

Morbilliform exanthem, often pruritic, is a frequent presentation of drug allergy that occurs about four to 21 days after starting a new medication. This type of skin reaction requires discontinuation of the agent. It will
subsequently resolve either spontaneously or after treatment with systemic antihistamines and/or corticosteroids applied topically or given systemically or both. Repeat administration of the causative agent will result in recurrence of CARD [4].

Our patient developed a dual doxycycline-associated CARD: photosensitivity and morbilliform exanthem. Both skin side-effects coincided. Similarly, both CARD promptly resolved after stopping the doxycycline and initiating topical and system interventions to alleviate the drug-associated symptoms and lesions.

Conclusions
CARD is common. Antibiotics are frequently associated with a CARD. These include not only a generalized skin eruption but also photosensitivity. Classes of antibiotics associated with photosensitivity include cephalosporins, fluoroquinolones, penicillins, sulfonamides, and tetracyclines. We observed a woman who developed photosensitivity and a morbilliform exanthem to doxycycline after the drug was prescribed to treat her rosacea. The photosensitivity presented as pruritic macular erythema on sun-exposed areas of the face, neck, and forearms. The morbilliform exanthem was observed as erythematous macules and patches on the flanks and abdomen. Both of the CARDs to doxycycline resolved within two weeks after initiation of oral antihistamines, oral prednisone, and topical triamcinolone. Albeit seldom, concurrent CARD may occur; in our patient, doxycycline-associated dual CARD - photosensitivity and morbilliform exanthem - occurred.

Additional Information
Disclosures
Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: Dr. Philip R. Cohen declare(s) personal fees from ParaPRO. Dr. Cohen is a consultant for ParaPRO. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Loh TY, Cohen PR: Ketoprofen-induced photoallergic dermatitis. Indian J Med Res. 2016, 144:805-806. 10.4103/ijmr.IJMR_626_16
2. Ashourian N, Cohen PR: Chapter 4: Systemic antibacterial agents. Comprehensive Dermatologic Drug Therapy. Stephen E. Wolverton (ed): Saunders/Elsevier, Philadelphia, PA; 2007. 59-74.
3. Lugovsíc-Mihlíč, D, Darancíč T, Ferčík I, Vukošek F, Žapundžič I, Česić D: Drug-induced photosensitivity - a continuing diagnostic challenge. Acta Clin Croat. 2017, 56:277-283. 10.1007/s10584-017-0602-11
4. Stern RS: Clinical practice. Exanthematous drug eruptions. N Engl J Med. 2012, 366:2492-2501. 10.1056/NEJMcp1104080
5. Nitya S, Deepa K, Mangaiarikkarasi A, Karthikeyan K: Doxycycline induced generalized bullous fixed drug eruption - a case report. Int J Young Pharm. 2013, 5:195-196. 10.1016/j.ijyp.2013.12.001
6. Miller KK, Chu J, Patel R, Ramino H: Drug-induced subacute cutaneous lupus erythematosus related to doxycycline. Dermatol Online J. 2011, 17:5.
7. Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O: Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. Br J Dermatol. 2012, 166:1533-1541. 10.1111/j.1365-2133.2012.10845.x
8. Wriston DJ, Norfolk ER, Smith LM, Chen G, Bulbin DE: Doxycycline-induced antinuclear antibody and antineutrophil cytoplasmic antibody associated vasculitis: a case report and literature review. Case Rep Rheumatol. 2020, 2020:701155/2020/385567
9. Cohen PR: What is the cause of the tender erythema? Is bupropion-associated phototoxic reaction [DermNet] - The Dermatologist. 2015, 25:46-50.
10. Monteiro AF, Rato M, Martins C: Drug-induced photosensitivity: phototoxic and phototopic reactions. Clin Dermatol. 2016, 34:571-581. 10.1016/j.clindermatol.2016.05.006
11. Khandpur S, Porter RM, Boulton SJ, Anstey A: Drug-induced photosensitivity: new insights into pathomechanisms and clinical variation through basic and applied science. Br J Dermatol. 2017, 176:902-909. 10.1111/bjd.14955
12. Vinks SA, Heijerman HG, de Jonge P, Bakker W: Photosensitivity due to ambulatory intravenous ceftazidime in cystic fibrosis patient. Lancet. 1995, 345:1221-1222. 10.1016/0140-6736(95)9058-t
13. Urbina F, Barrios M, Sudy E: Photolocalized purpura during ciprofloxacin therapy. Photodermatol Photoinmunol Photomed. 2006, 22:111-112. 10.1111/j.1600-0781.2006.00210.x
14. Dawe RS, Rohstock SH, Sanderson JB, Thomson EM, Ferguson J: A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br J Dermatol. 2003, 149:1232-1241. 10.1111/j.1365-2133.2003.05582.x
15. Delaunay I, Chassain K, Sarre ME, Avenel-Audran M: A drug not recognized as a photosensitizer?. Contact Dermatitis. 2019, 81:143-144. 10.1111/cod.13265
16. De D, Dogra S, Kaur I: Dapsone induced acute photosensitivity dermatitis; a case report and review of literature. Lepr Rev. 2007, 78:401-404.
17. Zhou W, Moore DE: Photosensitizing activity of the anti-bacterial drugs sulfamethoxazole and trimethoprim. J Photochem Photobiol B, 1997, 37:65-72. 10.1016/s1011-1344(97)00746-4
18. Blank H, Cullen SI, Catalano PM: Photosensitivity studies with demethylchlortetracycline and doxycycline.
19. Goetze S, Hiernickel C, Elsner P: Phototoxicity of doxycycline: a systematic review on clinical manifestations, frequency, cofactors, and prevention. Skin Pharmacol Physiol. 2017, 30:76-80. 10.1159/000458761

20. Frost P, Weinstein GD, Gomez EC: Phototoxic potential of minocycline and doxycycline. Arch Dermatol. 1972, 105:681-683. 10.1001/archderm.1972.01620080011005